Table 1.
Distribution of clinico-pathological characteristics at diagnosis and after neoadjuvant chemoradiation in the overall study population, and according with the levels of M1/M2.
Fig 1.
Correlation between the number of TAMs and circulating monocyte count at diagnosis.
Empty circles represent the number of TAMs and circulating monocyte in each patient, linear trend has been also provided (p value, and X2 have been calculated applying linear regression model).
Fig 2.
A-B)Examples of double staining immunohistochemistry to identify M1 and M2 TAMs in cervical cancer patients. Expression of CD68 is indicated by brown cytoplasmic/membranous staining. The expression of transcription factors pSTAT and c-MAF is indicated by red nuclear staining. Representative examples have been presented of cervical cancer patients with high numbers of M1 (CD68+pSTAT1+) cells (A; arrows indicate M1 cells), and M2 (CD68+c-MAF+) cells (B; arrows indicate M2 cells) (original magnification 200X; insert magnification 1000X). C) Overall survival curves in LACC patients with high and low M1 levels (solid line = high M1, dashed line = low M1). D) Overall survival curves in LACC patients with high and low M2 levels (solid line = high M2, dashed line = low M2).
Table 2.
Univariate and multivariate analysis of clinical-pathological parameters as predictors of complete pathologic response after preoperative chemoradiation.
Fig 3.
Disease-free (A) and Overall (B) survival curves in LACC patients with high and low M1/M2 levels (solid line = high M1/M2, dashed line = low M1/M2).
Table 3.
Univariate and multivariate analysis of clinical-pathological parameters as predictors of disease-free and overall survival.